Saruparib

AstraZeneca is testing saruparib (AZD5305), a next-generation PARP inhibitor engineered to hit only PARP1 and leave PARP2 alone, in Phase 3 for BRCA1/2 or PALB2-mutant HR-positive/HER2-negative advanced breast cancer (EvoPAR-Breast01, NCT06380751) [1]. The commercial bet is that PARP1 selectivity will allow full-dose combination with camizestrant (AstraZeneca's oral selective estrogen receptor degrader, or SERD) without the myelosuppression that limits older PARP inhibitors [2]. If it works, saruparib becomes the successor to olaparib (Lynparza), a franchise that generated approximately $3.7B in 2024 product sales and faces US loss of exclusivity as early as 2027 [3].

Novel compound, never approved anywhere. Phase 3 in first-line HR-positive/HER2-negative BRCA1/2/PALB2m advanced breast cancer (EvoPAR-Breast01, NCT06380751), enrolling 500 patients, with progression-free survival as the primary endpoint against physician's choice CDK4/6 inhibitor plus endocrine therapy or camizestrant monotherapy in a three-arm design [1]. AstraZeneca is running a parallel Phase 3 program in metastatic hormone-sensitive prostate cancer combining saruparib with AR pathway inhibitors (EvoPAR-Prostate01), described in Future Oncology in 2026 [4]. No FDA breakthrough or fast track designations have been publicly disclosed for either program. The Phase 1 monotherapy dose-escalation (PETRA) established the drug's differentiating tolerability profile: substantially less anemia and thrombocytopenia than first-generation PARP inhibitors, which is what enabled the combination Phase 3 strategy [2]. Additional Phase 1 work is ongoing, including a completed combination study with darolutamide in newly diagnosed prostate cancer (NCT05938270, n=113) [5] and an in-human absolute bioavailability pharmacokinetics study (NCT06713369) [6]. Detailed efficacy results from NCT05938270 have not been fully disclosed in peer-reviewed publication as of this writing; the Phase 3 prostate program advanced based on tolerability and biomarker readouts. Expected primary PFS readout for EvoPAR-Breast01 falls in the 2027-2028 window based on standard follow-up duration in HR-positive/HER2-negative first-line trials.

PARP1 is a repair protein cells use to fix single-strand DNA breaks. Block PARP1, and those breaks become double-strand breaks during DNA replication. In normal cells, BRCA1 and BRCA2 (or their partner PALB2) clean up double-strand breaks through homologous recombination, a high-fidelity repair pathway. In cancer cells with BRCA1/2 or PALB2 mutations, that backup is broken. So PARP inhibition plus BRCA mutation equals synthetic lethality: the cell can't repair its DNA, and it dies. Every existing PARP inhibitor (olaparib, talazoparib, niraparib, rucaparib) also blocks PARP2, a related enzyme that matters for bone marrow function. Hitting PARP2 causes anemia, low platelets, and myelosuppression. That toxicity forces dose reductions and blocks combinations with other cancer drugs. Saruparib is more than 500-fold selective for PARP1 over PARP2, and Phase 1 tolerability data support the thesis that AstraZeneca solved the combinability problem [2]. That is the entire commercial argument. The combination rationale with camizestrant runs deeper than dose-additivity. SERDs bind the estrogen receptor and trigger its degradation, shutting down ER-driven proliferation in HR-positive tumors. Preclinical work suggests ER signaling upregulates components of homologous recombination repair, meaning ER blockade may sensitize tumor cells to PARP inhibition even before BRCA-mutation-driven synthetic lethality kicks in. In practice: ER blockade plus DNA repair blockade attacks two independent survival pathways simultaneously. Genetic validation of the target is airtight for BRCA1/2. Synthetic lethality with BRCA mutations has driven four approved PARP inhibitors and billions in oncology revenue [7]. What's new here is the selectivity profile, not the core target biology. Open Targets scores PARP1 at 0.579 for breast cancer evidence, 0.621 for ovarian cancer, reflecting a decade of clinical validation across BRCA-mutant tumors.

EvoPAR-Breast01 (NCT06380751) is a three-arm Phase 3, n=500, in first-line HR-positive/HER2-negative (IHC 0, 1+, or 2+ ISH non-amplified) advanced breast cancer with germline or somatic BRCA1/2 or PALB2 mutations. Arms: saruparib plus camizestrant, physician's choice CDK4/6 inhibitor plus endocrine therapy, or camizestrant monotherapy. Primary endpoint is PFS. Sponsor: AstraZeneca. Currently recruiting [1]. Two things stand out. First, the biomarker gate. BRCA1/2 mutation status is fully validated for PARP inhibitor response, with olaparib approved in gBRCA-mutant HER2-negative metastatic breast cancer based on OlympiAD (though OlympiAD enrolled pretreated patients and compared against physician's choice chemotherapy, not against CDK4/6i plus endocrine therapy). PALB2 inclusion is a biological extension: PALB2 is BRCA2's obligate partner in HR repair, and retrospective data (including the TBCRC 048 basket trial) show responses to olaparib in PALB2-mutant breast cancer, but no PARP inhibitor carries a PALB2-specific label. PALB2 mutations are also a substantially smaller slice of the eligible population than BRCA1/2. Second, the comparator (CDK4/6i plus endocrine therapy) is the current first-line standard of care in HR-positive/HER2-negative disease, which is a legitimate hurdle. No PARP inhibitor has been validated head-to-head against a CDK4/6i-plus-ET backbone in the first-line setting. EvoPAR-Breast01 is the trial that has to prove this step. The concern: the camizestrant monotherapy arm creates attribution ambiguity. If saruparib plus camizestrant beats camizestrant alone, is that saruparib adding benefit, or the camizestrant backbone already competing with CDK4/6 inhibitors? Careful cross-arm analysis will be needed to isolate the saruparib contribution. Enrollment target of 500 patients across three arms is not oversized for HR-positive/HER2-negative BRCA-mutant disease. Recruitment pace is the execution risk given the narrow patient pool (roughly 5-7% of HR-positive/HER2-negative breast cancer carries BRCA1/2 mutations, and PALB2 adds only 1-2% more).

Our model estimates a 34% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding, more secondary endpoints than usual, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is moderate. The BRCA-mutant subgroup is the safest bet in PARP inhibition, but HR-positive/HER2-negative first-line is dominated by CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) with 24-30 month PFS in unselected populations. Saruparib plus camizestrant has to beat that meaningfully. A PFS delta of 3-4 months in a BRCA-selected population may not carry the payer conversation for a novel doublet. PALB2 patients, who compose the smaller slice of the eligible population, carry additional uncertainty because no PARP inhibitor has a PALB2-specific approval anywhere. Safety risk shifts the story from older PARP inhibitors. First-generation PARPs cause dose-limiting myelosuppression, particularly in combination regimens. Saruparib's PARP1 selectivity was designed to solve this, and Phase 1 data supported the thesis [2]. Long-term follow-up will still need to surface MDS/AML signals if they exist. This is a known class effect of PARP inhibition regardless of PARP2 sparing, because the drug still forces double-strand breaks in replicating cells. That's a multi-year post-approval concern. Resistance mechanisms via BRCA reversion mutations and restored homologous recombination remain unresolved for the entire class [7]. Execution risk: three arms with a not-yet-fully-approved combination partner (camizestrant) means AstraZeneca is running two novel-mechanism programs in parallel. Camizestrant's SERENA-6 Phase 3 (n=315, ESR1-mutant HR-positive/HER2-negative advanced breast cancer, camizestrant plus ongoing CDK4/6i versus continued AI plus CDK4/6i, PFS primary endpoint) reported positive results in 2025 supporting an initial regulatory path in the ESR1-mutant switch setting. Broader first-line labels are still pending. If camizestrant's development stumbles, the EvoPAR-Breast01 combination arm becomes an orphan. Commercial risk: even with approval, positioning against generic olaparib is a payer conversation. Lynparza US loss of exclusivity is as early as 2027; AstraZeneca is in active patent litigation against Sandoz, Cipla, and other ANDA filers, with a composition-of-matter patent extending to approximately 2031 as a backstop [3]. AstraZeneca will price saruparib as a differentiated combination product, but the class-of-one narrative has to hold up against a cheap incumbent whose entry timing is itself the subject of ongoing litigation.

Worth watching. This is AstraZeneca's PARP franchise defense play. Lynparza (olaparib) generated approximately $3.7B in 2024 product sales, with US loss of exclusivity as early as 2027 subject to ongoing patent litigation [3]. Saruparib is engineered as the successor product, designed to be combinable with the rest of the oncology portfolio: camizestrant in breast, AR pathway agents in prostate, potentially ADCs downstream. The signal to check first: EvoPAR-Breast01 interim safety data on combination tolerability. If saruparib plus camizestrant runs at full doses without dose reductions, the combinability thesis is validated and every downstream AstraZeneca oncology combination becomes strategically viable. If dose reductions creep in, the story collapses to "slightly better olaparib" and the franchise defense fails. Secondary check: EvoPAR-Prostate01 readouts in mHSPC combining saruparib with darolutamide or other AR pathway inhibitors [4]. If the combination beats AR-inhibitor monotherapy in a broader-than-HRR-mutant population, that opens a substantially larger prostate market than the current PARP inhibitor niche, which is currently restricted to HRR-mutant post-progression settings. Check back: 2026-Q4 for combination safety data disclosures at ESMO or SABCS. 2027-2028 for the EvoPAR-Breast01 primary PFS readout, alongside the Lynparza US LOE window. AstraZeneca has the balance sheet ($58.7B in 2024 revenue) and the oncology commercial infrastructure to execute [3]. The open question is whether PARP1 selectivity delivers the Phase 3 tolerability profile it showed in Phase 1, and whether the combination can clear the CDK4/6i-plus-ET bar in a first-line setting no PARP inhibitor has previously beaten.